Merck Sharp & Dohme Corporation

Merck & Company, Inc.

Albany Molecular Research, Inc.

Other

Nicox S.a.

Msd Italia S.r.l.

Orchid Pharma Ltd.

Ravi P Nargund

Arthur A Patchett

Lihu Yang

Zhixiong Ye

Shuwen He

Anandan Palani

Raman Kumar Bakshi

Linus S Lin

Liangqin Guo

Lin Yan

Pei Huo

Xing Dai

Iyassu Sebhat

James R Tata

Amjad Ali

Peng Li

Qun Dang

Dong Xiao

Jian Liu

Songnian Lin

Xuanjia Peng

Feroze Ujjainwalla

Danqing D Feng

Hong Liu

Dmitri A Pissarnitski

Ahmet Kekec

William K Hagmann

Hubert B Josien

Peter Guzzo

Casey Cameron McComas

Michael Man-Chu Lo

David B Johnston

Zhicai Wu

Ping Liu

Purakkattle J Biju

Richard Soll

Harry R Chobanian

Christina B Madsen-Duggan

Thomas F Walsh

Bin Hu

Mark T Goulet

Leonardus H T Van Der Ploeg

Elisabetta Bianchi

Antonello Pessi

Gregori J Morriello

Zhi-Cai Shi

Yan Guo

Qiaolin Deng

Min K Park

Tesfaye Biftu

Prasun K Chakravarty

Michael W Miller

Kathleen M Rupprecht

Steven L Colletti

Tomi K Sawyer

Robert K Baker

Jonathan R Young

Cheng Zhu

Derun Li

Nicoletta Almirante

Bing Li

Robert J DeVita

Clare London

Linda Brockunier

Zhengxia Chen

Andrew William Stamford

Joseph A Kozlowski

Nigel J Liverton

Yongxin Han

Hao Wu

Alexander Pasternak

Shrenik K Shah

Kun Liu

Tao Guo

Barbara A Pio

Wensheng Yu

Dong-Ming Shen

Hongjun Zhang

Sheo B Singh

Thomas Joseph Tucker

Zhijian Lu

Duane E DeMong

Thomas J Greshock

Kevin Tyler Chapman

Guoqing Li

Bowei Wang

Ying-Duo Gao

Shuzhi Dong

Linda L Chang

Abdelghani Achab

De-Yi Yang

Frank Narjes

David G Melillo

Shouwu Miao

Uwe Koch

Timothy A Blizzard

Christopher W Plummer

Qinglin Pu

Quang T Truong

Zhiqiang Zhao

Long-acting co-agonists of the glucagon and GLP-1 receptors are described.

Long-acting co-agonists of the glucagon and GLP-1 receptors

This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R, and Rare as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Substituted carbapenems for the treatment of bacterial infections

Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.

Insulin dimer-incretin conjugates

An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.

Insulin receptor partial agonists

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Co-agonists of the glucagon and GLP-1 receptors

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Compounds inhibiting leucine-rich repeat kinase enzyme activity

Growing community of inventors

East Brunswick, NJ, United States of America

Ravi P Nargund